Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.
From Trial to Treatment: Applying the Latest Evidence in mCSPC Management
Clinicians across four cities weigh ARASEC and ARANOTE trial data, drug interactions, and access barriers in mCSPC treatment decisions.
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
3
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
4
AI system links surgical gestures with postoperative outcomes
5